-+ 0.00%
-+ 0.00%
-+ 0.00%

MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer’s Disease and Dementia

Barchart·07/14/2026 07:35:00
Listen to the news

TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precision-based cannabinoids, today announced positive results from the Phase II LiBBY (Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol) clinical trial evaluating the Company’s proprietary oral cannabinoid formulation for the treatment of agitation in patients with advanced dementia. The results were presented by the LiBBY team at AAIC in London, United Kingdom on July 14, 2026.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.